Histogenics Corporation to Present at the 37th Annual Canaccord Genuity Growth Conference
July 26 2017 - 8:30AM
Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative
medicine company focused on developing and commercializing products
in the musculoskeletal space, today announced that Adam Gridley,
President and Chief Executive Officer of Histogenics, will present
at the 37th Annual Growth Conference on Wednesday, August 9, 2017
at 10:00 AM EDT at the InterContinental Boston in Boston, MA.
This presentation will be webcast live and may be accessed by
visiting the Investor Relations section of Histogenics’ website at
www.histogenics.com. The webcast will be available on Histogenics’
website for 45 days following the conference.
About Histogenics
Corporation
Histogenics is a leading regenerative medicine
company developing and commercializing novel tissue therapies that
may offer more rapid and durable recoveries for patients with pain
and loss of function due to musculoskeletal conditions.
Histogenics’ regenerative medicine platform combines expertise in
cell processing, scaffolding, tissue engineering and bioadhesives
to create tissue ex-vivo. Histogenics’ first investigational
product candidate, NeoCart is designed to treat cartilage defects
in the knee. The Company recently completed enrollment of its
NeoCart Phase 3 clinical trial and expects to report topline data
in the third quarter of 2018. NeoCart is designed to exhibit
characteristics of articular, hyaline cartilage prior to and upon
implantation into the knee and therefore does not rely on the body
to make new cartilage. As a result, NeoCart is the only product in
development or on the market with a one-year primary superiority
endpoint as compared to the standard of care. There are more than
500,000 or more knee cartilage procedures in the United States each
year, with many healthy active adults avoiding treatment as they
seek other alternatives. Left untreated, even a small cartilage
defect can expand in size and progress to debilitating
osteoarthritis, ultimately necessitating a joint replacement
procedure. Osteoarthritis is more common in adults over the age of
50, but the condition and precursors of the condition can be
observed much earlier, and cartilage damage is believed to be one
of the leading contributors of this disease. For more information,
please visit www.histogenics.com.
Contact:
Investor Relations
Tel: +1 (781) 547-7909
InvestorRelations@histogenics.com
Histogenics (NASDAQ:HSGX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Histogenics (NASDAQ:HSGX)
Historical Stock Chart
From Sep 2023 to Sep 2024